51
Analytical study on certain drugs which treat brain agency and deterioration.

Analytical study on certain drugs which treat brain agency and deterioration

  • Upload
    seanna

  • View
    12

  • Download
    0

Embed Size (px)

DESCRIPTION

Analytical study on certain drugs which treat brain agency and deterioration. This thesis consists of four parts :- PartI:Stability indicating methods for the determination of Pyritinol dihydrochloride . Part II: Stability indicating colorimetric method for the determination of piracetam. - PowerPoint PPT Presentation

Citation preview

Page 1: Analytical study on certain drugs which treat brain agency  and deterioration

Analytical study on certain drugs which treat brain

agency and deterioration.

Page 2: Analytical study on certain drugs which treat brain agency  and deterioration

This thesis consists of four parts:- PartI:Stability indicating methods for the

determination of Pyritinol dihydrochloride. Part II: Stability indicating colorimetric method for

the determination of piracetam. Part III : Stability indicating colorimetric

method for the determination of meclophenoxate hydrochloride.

Part IV :Stability indicating methods for the determination of vincamine in presence of its degradation product.

Page 3: Analytical study on certain drugs which treat brain agency  and deterioration

Part I :Stability indicating methods for the

determination of Pyritinol dihydrochloride.

Page 4: Analytical study on certain drugs which treat brain agency  and deterioration

This part includes a general introduction about the chemistry of pyritinol dihydrochloride,mode of action.

A review on the reported methods used for pyritinol dihydrochloride quantitative determination.

Page 5: Analytical study on certain drugs which treat brain agency  and deterioration

Section(A): Determination of pyritinol

dihydrochloride in presence of its precursor and its degradation

product by derivative spectrophotometry.

Page 6: Analytical study on certain drugs which treat brain agency  and deterioration

The structure of pyritinol

dihydrochloride:-

How to obtain the precursor ?

How to obtain the degradation product?

N NCH3

HOS -S

CH3

OH

OH

2HCl.. H2O

HO

N N NCH3

HOS -S

CH3

OH

OHHO

CH3

HO

HO

Zn pd. /1NHCl

1hr2

SH.HCl

mol.wt 221

N N NCH3

HOS -S

CH3

.2HCl

OHHO

CH3

HO

HO

H2O2 30% v/v

leave 1hr.at room temp.

2SO3H.HCl

OH

mol.wt 269

Page 7: Analytical study on certain drugs which treat brain agency  and deterioration

I.A.1First derivative spectrophotometric

determination of pyritinol dihydrochloride in presence of its

precursor and its degradation product.

Page 8: Analytical study on certain drugs which treat brain agency  and deterioration

Figure ( 1 ): Absorption spectra of Pyritinol dihydrochloride 20 µg. ml-1 ,)———(

precursor 14 µg. ml-1 (— — — — ) and degradation product 6 µg. ml-1 (--------- ) Using 0.1N hydrochloric acid as a solvent

Page 9: Analytical study on certain drugs which treat brain agency  and deterioration

Figure ( 2 ): First – derivative absorption spectra of Pyritinol dihydrochloride 20 µg. ml-1 (———), precursor 14 µg. ml-1 (— — — — ) and degradation product 6 µg. ml-1 (---------- ).  Using 0.1N hydrochloric acid as a solvent

 

Page 10: Analytical study on certain drugs which treat brain agency  and deterioration

Figure ( 3 ): First – derivative absorption spectra of 6-22 µg. ml-1 Pyritinol dihydrochloride

Page 11: Analytical study on certain drugs which treat brain agency  and deterioration

0

0.05

0.1

0.15

0.2

0.25

0.3

0.35

0 5 10 15 20 25

Concenteration g.ml-1

Pe

ak

am

plit

ud

e

Figure (4): Linearity of the peak amplitude of the first derivative at 284.4nm to the corresponding concentration of pyritinoldihydrochloride.   

Page 12: Analytical study on certain drugs which treat brain agency  and deterioration

I.A.2.Derivative ratio zero crossing method for the determination of pyritinol dihydrochloride in presence of its

precursor and its degradation product .

Page 13: Analytical study on certain drugs which treat brain agency  and deterioration

A

) pyritinol(/deg.prod.(

Figure ( 5 ): Zero order of ratio spectra of 6-20 µg. ml-1

pyritinol.2HCl / deg. Product (———)and 14 µg. ml-1 precursor/ deg. Product (-------) using 6 µg. ml-1 deg. product as a divisor.

Page 14: Analytical study on certain drugs which treat brain agency  and deterioration

dA)pyritinol.2H

Cl/ deg. prod.(/dλ

Figure ( 5 ): First order of ratio spectra of 6-20µg. ml-1

pyritinol.2HCl / deg. Product (———)and 14 µg. ml-1 precursor/ deg. Product (-------) using 6 µg. ml-1 deg. product as a divisor.

Page 15: Analytical study on certain drugs which treat brain agency  and deterioration

-12

-10

-8

-6

-4

-2

0

0 5 10 15 20 25

Concenteration g.ml-1

Pea

k am

pli

tud

e

Figure (7): Linearity of the peak amplitude of the first derivative of

the ratio spectra at 316 nm to the corresponding

concentration pyritinol dihydrochloride.

Page 16: Analytical study on certain drugs which treat brain agency  and deterioration

Table (I): determination of pyritinol dihydrochloride in laboratory prepared mixtures by the proposed procedures.

Concentration (µg/ml) Percentage % First derivative spectrophotometry

Derivative ratio- zero crossing

Pyritinol.2HCl

Precursor

Deg.produtt Pyritiol.2HCl

Precursor Deg.product

Recovery % Recovery %

Pyritinol.2HCl Pyritinol. 2HCl

17.00 1.00 2.00 85% 5% 10% 98.23% 98.56%

16.00 2.00 2.00 80% 10% 10% 100.77% 100.23%

15.00 2.00 3.00 75% 10% 15% 99.91% 99.86%

14.00 2.00 4.00 70% 10% 20% 99.05% 99.98%

13.00 1.00 5.00 65% 5% 25% 100.91% 100.97%

12.00 2.00 6.00 60% 10% 30% 102.07% 101.95%

11.00 2.00 7.00 55% 10% 35% 99.83% 99.97%

10.00 2.00 8.00 50% 10% 40% 100.39% 100.71%

9.00 2.00 9.00 45% 10% 45% 100.34% 100.94%

8.00 2.00 10.00 40% 10% 50% 100.12% 99.98%

Mean           100.15 100.11

S.D.           0.615 0.572

Page 17: Analytical study on certain drugs which treat brain agency  and deterioration

Table (II): Determination of pyritinol dihydrochloride in encephabol tablets by the proposed procedures.

* Average of six determinations. **Spectrophotometric method

Encephabol tablets claimed to contain 200 mgBatch number

First derivative spectro photometry

Derivative ratio-zero crossing

Compendial method**

 % Found

 

 % Found

 Recovery % ± S.D.*

 

19578 99.27 99.43 99.36 ± 0.421

19357 99.61 99.85 99.72 ± 0.854

19722 99.93 100.41 99.91 ± 0.739

Page 18: Analytical study on certain drugs which treat brain agency  and deterioration

Table (III): Statistical comparison for the results obtained by the proposed method and the compendial method for the analysis of pyritinol dihydrochloride in pure powder form.

The figures in parenthesis are the corresponding tabulated values at P=0.05.*Spectrophotometric method

  First derivative spectrophotometry

Derivative ratio- zero crossing method.

Compendial method*

  Pyritinol dihydrochloride

Pyritinol dihydrochloride Pyritinoldihydrochloride

Mean 100.364 99.922 99.061

S.D. 1.497 1.172 1.053

Variance 2.241 1.375 1.109

N 9 8 6

F test 2.021 (4.82) 1.24 (4.88)  

Student’s t test 1.84 (2.160) 1.42 (2.179)  

Page 19: Analytical study on certain drugs which treat brain agency  and deterioration

Table (IV): Results of application of standard addition to the determination of pyritinol dihydrochloride by the proposed

method.

Batch number

Standard added(mg.ml-1)

First derivative spectro photometry

Derivative ratio-zero crossing

Pyritinol dihydrochloride

 Recovery % of added

 

 Recovery % of

added 19578 0.10

0.150.20

 

101.3199.3298.75

101.0099.06

100.92

Mean ± S.D.   99.79 ± 1.344 100.33 ±1.097

19357 0.100.150.20

 

98.9299.47

100.82

99.8799.36

100.56

Mean ± S.D.   99.73 ± 0.977 99.93 ± 0.602

19722 0.100.150.20

 

98.7598.75

100.82

99.38100.2698.82

Mean ± S.D.   99.44 ± 1.195 99.48± 0.725

Page 20: Analytical study on certain drugs which treat brain agency  and deterioration

Section (B): Determination of pyritinol dihydrochloride in presence of its precursor and its degradation product by

densitometric method.

Page 21: Analytical study on certain drugs which treat brain agency  and deterioration

Figure (12): TLC chromatogram of pyritinol dihydrochloride, its degradation product and its precursor .

A= Pyritinol dihydrochloride. Rf = 0.4

B= Degradation product. Rf = 0.5

C= Precursor. Rf = 0.66

Developing system: n-butanol : acetic acid : water (4:1:1 v/v/v).

Page 22: Analytical study on certain drugs which treat brain agency  and deterioration

Figure ) 13 (:

Scanning profile of TLCchromatogram of pyritinol

dihydrochloride at 300 nm.

Page 23: Analytical study on certain drugs which treat brain agency  and deterioration

0

1

2

3

4

5

6

7

8

0 5 10 15 20

Concentration g.spot-1

Inte

gra

ted

pe

ak

are

a

( x

10

-4)

Figure (14): Linearity of the area under the peak to the corresponding concentration of pyritinol dihydrochloride.

Page 24: Analytical study on certain drugs which treat brain agency  and deterioration

Table (V): Determination of pyritinol dihydrochloride in laboratory prepared mixtures by the proposed procedures.

Concentration (µg/ml) Percentage % Densitometric method

Pyritinol.2HCl Precursor Deg.product Pyritinol.2HCl Precursor Deg.productRecovery %

Pyritinol 2.HCl

900 50 100 90 5 10 99.98%

800 50 150 80 5 15 99.80%

700 100 200 70 10 20 100.06%

600 100 300 60 10 30 100.75%

500 100 400 50 10 40 98.96%

400 100 500 40 10 50 99.86%

300 100 600 30 10 60 99.51%

Mean           99.84

S.D.           0.54

Page 25: Analytical study on certain drugs which treat brain agency  and deterioration

Table (VI): Determination of pyritinol dihydrochloride in encephabol tablets by the proposed procedures.

* Average of four determinations. **Spectrophotometric method.

Encephabol tablets claimed to contain 200 mg

Batch number

Densitometric method Compendial method**

 % Found

 Recovery % ± S.D.*

19578 99.63 99.36 ± 0.421

19357 99.22 99.72 ± 0.854

19722 100.15 99.91 ± 0.739

Page 26: Analytical study on certain drugs which treat brain agency  and deterioration

Table (VII): Statistical comparison for the results obtained by the proposed method

and the compendial method for the analysis of pyritinol dihydrochloride in pure powder

form.

The figures in parenthesis are the corresponding tabulated values at P=0.05 (36).*Spectrophotometric method

  Densitometric method. Compendial method*

  Pyritinol dihydrochloride Pyritinol dihydrochloride

Mean 99.908 99.061

S.D. 0.848 1.053

Variance 0.719 1.109

N 8 6

F test 1.542(4.362)  

Student’s t test 1.67(2.179)  

Page 27: Analytical study on certain drugs which treat brain agency  and deterioration

Table (VIII): Results of application of standard addition to the determination of pyritinol dihydrochloride by the proposed method.

Batch number

Standard added(mg.ml-1)

Densitometric method

Pyritinol dihydrochloride

 Recovery % of added

 

19578 1.001.502.00

99.51100.3398.79

Mean ± S.D.   99.54± 0.770

19357 1.001.502.00

100.6299.4799.31

Mean ± S.D.   99.80 ± 0.714

19722 1.001.502.00

99.32100.6999.03

Mean ± S.D.   99.68 ± 0.886

Page 28: Analytical study on certain drugs which treat brain agency  and deterioration

Table (IX) : Assay parameters and method validation

* RSD%a , RSD%b the intraday, interday respectively (n=5) relative standard deviation of concentrations ( 12- 14µg/ml) for first derivative and derivative methods, and concentrations ( 7-9µg/spot) for densitometric method.

Parameter First Derivative spectrophotometery

Derivative ratio – zero crossing

Densitometric method

Pyritinol dihydrochloride

Pyritinol dihydrochloride

Pyritinol dihydrochloride

Range (µg.ml-1) 6-22 6-20 1-15 (µg.spot-1)

Slope 0.0143 -0.4751 0.439

Intercept 0.0082 -0.071 0.0844

Mean 100.364 99.922 99.908

S.D. 1.497 1.172 0.848

Variance 2.241 1.375 0.719

Coff. of variation 1.491 1.173 0.848

Correl. Coef.(r) 0.9994 0.9995 0.9998

* RSD%a 0.128- 0.203 0.132 – 0.197 0.378 –0.521

*RSD %b 0.136 –0.184 0.141 –0.175 0.554 –0.673

Page 29: Analytical study on certain drugs which treat brain agency  and deterioration

Section (C): Oxidation – reduction titrimetric method for the determination of pyritinol dihydrochloride in presence of its

degradation product.

Page 30: Analytical study on certain drugs which treat brain agency  and deterioration

The proposed reaction mechanism :

3Br2 + 6 es 6 Br - (x10)

R-S-S-R + 6H2O 2 RSO3H + 10 H + + 10 es(x6)

Add the the two equations

60 Br -30 Br2 + 6 R-S-S-R + 36 H2O 12 RSO3H + 60 H+ +

Therfore 30Br2 = 6 R-S-S-R

Since BrO3 - + 5Br - +6 H+ 3 Br2 + 3 H2O

Therfore 10 K BrO3 / K Br = 30 Br2 = 6 R-S-S-R

1M K BrO3 / K Br = 6 R-S-S-R / 10

1 ml N/40 K BrO3 / K Br = 6 R-S-S-R / (6x10x40x1000)

= 441/(400x1000) = 1.1025 mg

Where R-S-S-R =

 

N NCH3

HOS -S

CH3

OH

OH

2HCl.. H2O

HO

Page 31: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XI) : Determination of pyritinol dihydrochloride in laboratory prepared mixtures by the proposed method .

Weight (mg) Percentage Titrimetricmethod

Pyritinol dihydrochlorid

e

Degradation product

Pyritinol dihydrochlorid

e

Degradation product

Recovery %

Pyritinol dihydrochloride

15 5 75% 25% 101.04

10 10 50% 50% 100.12

5 15 25% 75% 101.79

Mean       101.13

S.D.       0.740

Page 32: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XII): Determination of pyritinol dihydrochloride in encephabol tablets by the proposed procedures.

* Average of six determinations. **Spectrophotometric method

Encephabol tablets claimed to contain 200 mgBatch number

Titrimetric method Compendial method**

 % Found

 

 Recovery % ± S.D.*

19578 101.50 99.36 ± 0.421

19357 100.13 99.72 ± 0.854

19722 98.59 99.91 ± 0.739

Page 33: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XIII): Statistical comparison for the results obtained by the proposed method and the compendial method for the analysis of pyritinol dihydrochloride in pure powder form.

The figures in parenthesis are the corresponding tabulated values at P=0.05. *Spectrophotometric method

  Titrimetric method Compendial method*

 Pyritinol dihydrochloride Pyritinol dihydrochloride

Mean 99.928 99.061

S.D. 1.566 1.053

Variance 2.452 1.109

N 6 6

F test 2.211 (5.05)  

Student’s t test 1.115 (2.228)  

Page 34: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XIV): Results of application of standard addition to the determination of pyritinol dihydrochloride by the proposed method.

Batch number

Standard added(mg.ml-1)

Titrimetric method

Pyritinol dihydrochloride

 Recovery % of added

19578 1.001.502.00

99.32100.4098.23

Mean ± S.D.   99.31± 1.085

19357 1.001.502.00

101.5698.79

100.61

Mean ± S.D.   100.32 ± 1.407

19722 1.001.502.00

99.13101.5099.06

Mean ± S.D.   99.89 ± 1.388

Page 35: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XV) : Assay parameters and method validation

* RSD%a , RSD%b the intraday, interday respectively (n=3) relative standard deviation of concentrations ( 5 – 10 mg) .

ParameterTitrimetric method

Pyritinol dihydrochloride

Range (mg) 1 – 20

Mean 99.928

S.D. 1.566

Variance 2.452

Coff. of variation 1.567

* RSD%a 0.461 – 0.511

*RSD %b 0.673 – 0.562

Page 36: Analytical study on certain drugs which treat brain agency  and deterioration

Part IIStability indicating colorimetric method for the

determination of piracetam.

Page 37: Analytical study on certain drugs which treat brain agency  and deterioration

- This part includes a general introduction about the chemistry and mode of action of piracetam.

- A review on the reported methods for its quantitative determination.

-Stability indicating colorimetric method for the determination of piracetam using ninhydrin reagent.

Page 38: Analytical study on certain drugs which treat brain agency  and deterioration

 -Structure of piracetam.   

N

O

O

NH2 

-The proposed reaction mechanism for preparing the degradation product  

N

O

O

NH21 N NaOH

reflux 1 hr

N

O

O

OH

+ NH3

 

Page 39: Analytical study on certain drugs which treat brain agency  and deterioration

-The proposed reaction mechanism of piracetam with ninhydrin: 

 

 N

O

O

NH2

O

OOH

OH N

O

O

N

O

O

+

+ 2 H2O

 

Page 40: Analytical study on certain drugs which treat brain agency  and deterioration

Figure (15): Absorption spectra of

Piracetam in water 100 µg. ml-1 ).……(

Ninhydrin 4( % _ _ _ _ _ )

Colored product 30 µg. ml-1 (_______.)

 

Page 41: Analytical study on certain drugs which treat brain agency  and deterioration

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0 2 4 6 8 10

Volume (ml) of ninhydrin solution

Ab

so

rba

nc

e

Figure (20): Effect of volume (ml)of ninhydrin solution on the

absorbance of the colored product.

Page 42: Analytical study on certain drugs which treat brain agency  and deterioration

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0 2 4 6 8

pH

Ab

so

rba

nc

e

Figure (21): Effect of pH on the absorbance of the colored product. 

Page 43: Analytical study on certain drugs which treat brain agency  and deterioration

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0 5 10 15 20 25 30

Heating time in min.

Ab

so

rba

nc

e

Figure (22): Effect of heating time on the absorbance of the colored product.

Page 44: Analytical study on certain drugs which treat brain agency  and deterioration

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0 0.5 1 1.5

Volume (ml) of pyridine

Ab

so

rba

nc

Figure (23): Effect of volume (ml) of pyridine on the absorbance of the colored product.

Page 45: Analytical study on certain drugs which treat brain agency  and deterioration

Figure (18): Absorption spectra of colored product ( piracetam with ninhydrin) 10-50 μg. ml-1

Page 46: Analytical study on certain drugs which treat brain agency  and deterioration

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

0 20 40 60

Concentration g.ml-1

Ab

so

rba

nc

e

Figure (19): Linearity of the absorbance of the colored product of

piracetam with ninhydrin to the corresponding

concentration of piracetam.

Page 47: Analytical study on certain drugs which treat brain agency  and deterioration

Concentration (µg/ml) Percentage % NinhydrinMethod

Piracetam Degradation product

PiracetamDegradation product

Recovery %

Piracetam

45 5 90% 10% 98.32

40 10 80% 20% 99.24

35 15 70% 30% 101.06

30 20 60% 40% 100.25

25 25 50% 50% 98.89

20 30 40% 60% 101.70

15 35 30% 70% 98.88

10 40 20% 80% 100.54

Mean       99.86

S.D.       1.201

Table (XVI): Determination of piracetam in laboratory prepared mixtures by the proposed

procedures.

Page 48: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XVII): Determination of piracetam in nootropil and stimulan by the proposed procedures.

* Average of six determinations.

 **Titrimetric method

Commercial Name Dosage form Batch number

Ninhydrin method Compendial method**

 % Found

 Recovery % ± S.D.*

Nootropil

TabletCapsuleAmpoule

Syrup

001108001108501106600114

99.61 99.9398.95 98.45

98.63 ± 1.2799.32 ± 0.9398.21 ± 1.3198.11 ± 1.54

Stimulan

TabletCapsuleAmpoule

Syrup

1537166815941653

98.80 99.75 99.53

100.42

97.90 ± 0.9898.95 ± 1.3498.23 ± 1.2798.62 ± 1.47

Page 49: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XVIII): Statistical comparison for the results obtained by the proposed method and the compendial method for the

analysis of piracetam in pure powder form.

The figures in parenthesis are the corresponding tabulated values at P=0.05.*Titrimetric method

  Ninhydrin method Compendial method*

  Piracetam Piracetam

Mean 99.746 98.892

S.D. 1.171 1.023

Variance 1.371 1.046

N 9 6

F test 1.309 (4.82)  

Student’s t test 1.451 (2.160)  

Page 50: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XIX): Results of application of the standard addition to the

determination of piracetam by the proposed method.

CommercialName

Batchnumbe

r

Standardadded

mg.ml -1

Ninhydrinmethod

Batchnumber

Standardadded

mg.ml -1

NinhydrinMethod

   Piraceta

m

Recovery%of added

 Piraceta

m

Recovery %of added

Nootropil

001108tablet

 mean± S.D.

0.500.751.00

99.3298.23100.4099.31 ± 1.085

501106ampoule

 mean±S.D.

0.500.751.00

100.14100.50100.16

100.26±0.202

001108capusl

mean± S.D.

0.500.751.00

101.50102.5099.79101.26 ±1.370

600114syrup

 mean±S.D.

0.500.751.00

100.0099.6398.87

99.60±0.576

Stimulan 1537tablet

 mean± S.D.

0.500.751.00

99.1399.9398.70

98.25±0.620

1594ampoule

 mean±S.D.

0.500.751.00

99.2199.74

101.21100.05±1.036

  1668capsul

mean± S.D.

0.500.751.00

98.5698.7198.29

98.52± 0.210

1653syrup

 mean±S.D.

0.500.751.00

99.6898.9199.93

99.50±0.530

Page 51: Analytical study on certain drugs which treat brain agency  and deterioration

Table (XX) : Assay parameters and method validation

* RSD%a , RSD%b the intraday, interday respectively (n=5) relative standard deviation of concentrations (20-30 µg/ml) for piracetam

Parameter Ninhydrin method

Piracetam

Range (µg.ml-1) 10-50

Slope 0.0185

Intercept 0.0246

Mean 99.746

S.D. 1. 1707

Variance 1.37

Coff. of variation 1.173

Correl. Coef.(r) 0.9993

* RSD%a 0.223-0.317

*RSD %b 0.421-0.584